France Liver Diseases Therapeutics Market Report 2022 to 2030

France Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the France Liver Disease Therapeutics market will reach a value of $917 Mn from $635 Mn in 2022, growing at a CAGR of 4.7% during 2022-30. Liver Disease Therapeutics in France is dominated by a few domestic pharmaceutical companies such as Genfit, Sanofi, and Inventiva. The Liver Disease Therapeutics market in France is segmented into different types of disease and different therapy types. Some of the major factors affecting the France Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10FRPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Dr. Vishwa Modhia

Buy Now

France Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the France Liver Disease Therapeutics market will reach a value of $917 Mn from $635 Mn in 2022, growing at a CAGR of 4.7% during 2022-30.

France is a developed country in Western Europe with various overseas territories and islands on other continents and in the Indian, Pacific, and Atlantic oceans. In France, liver disease is a leading cause of death. Liver illnesses accounted for 2.6 % of all fatalities in France in 2019. According to the most recent WHO data, 7,382 people died from liver disease in France in 2020, accounting for 1.54% of all fatalities. In France, liver transplantation is a significant therapy option for advanced liver disease. Over 1,200 liver transplants were performed in France in 2020, making it one of the leading countries in the world for liver transplantation.

France ranks 154th in the world with an age-adjusted death rate of 6.54 per 100,000 population. The French government has also created a nationwide NAFLD prevention initiative. Public education campaigns and activities to promote healthy eating are part of the programme. France's government spent 12.2 % of its GDP on healthcare in 2020.

France Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

According to the French National Institute of Health and Medical Research (INSERM), alcohol-related liver disease is the most common type of liver disease in France, accounting for around half of all cases. In 2017, nearly 9,000 people were hospitalised in France for liver disease, with a 10-day average stay. France has a talented and productive workforce, as well as a demography that is continually changing. The quality of infrastructure and public service facilities boosts the efficiency of the country's corporate operations. These aspects could boost France's Liver Disease Therapeutics market.

Market Restraints

NAFLD prevalence is rising in France, as it is in many other wealthy countries. However, no drugs are currently licenced for the treatment of NAFLD, and lifestyle changes are sometimes difficult to initiate and maintain. In France, there is a dearth of understanding regarding liver illness, and many people who have it endure shame and discrimination. This can result in delays in diagnosis and treatment, as well as a refusal to seek medical attention. These factors may deter new entrants into the France Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Sanofi: Sanofi is a global pharmaceutical company headquartered in France. The company is involved in the development and commercialization of a range of liver disease therapeutics, including treatments for viral hepatitis and liver fibrosis
Genfit: Genfit is a French biotech company that is focused on the development of treatments for liver diseases, including non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC)
Inventiva: Inventiva is a French biopharmaceutical company that is focused on the development of therapies for fibrotic diseases, including liver fibrosis
Echosens: Echosens is a French medical device company that specializes in the development of non-invasive diagnostic tools for liver diseases, including FibroScan, which is used to measure liver stiffness
Gilead Sciences: Gilead Sciences is a global biopharmaceutical company that has a strong presence in France. The company is involved in the development and commercialization of a range of liver disease therapeutics, including treatments for viral hepatitis and liver fibrosis

Recent Notable Updates

January 2023: Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis ("NASH"), mucopolysaccharidoses ("MPS"), and other diseases with significant unmet medical needs, announced today that, after consulting with the U.S. Food and Drug Administration ("FDA"), the company has decided to modify the clinical development plan of lanifibranor for the treatment.

November 2022: GENFIT, a late-stage clinical-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases whose needs remain largely unmet, looks back today on the key elements communicated during the Pipeline Days, which were designed to assess the Company's clinical progress and strategy.

Healthcare Policies and Reimbursement Scenarios

In France, the regulatory authority for medicines is the National Agency for Medicines and Health Products Safety (ANSM). The ANSM is responsible for the evaluation, approval, and monitoring of drugs in France. In France, healthcare is financed through a combination of social security and complementary health insurance (CHI). Social security is mandatory for all residents of France and covers a portion of the cost of medical treatments, including drugs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.